Source comparison
CJC-1295 no DAC & Ipamorelin Science Explained: Peptide Comparison
Research teams frequently compare CJC-1295 no DAC and Ipamorelin to other growth hormone secretagogues to determine which combination produces the most physiologically relevant GH pulse profile without adverse endocrine effects. The table below contrasts key p
This comparison does not assign a generated winner or score.
- Research teams frequently compare CJC-1295 no DAC and Ipamorelin to other growth hormone secretagogues to determine which combination produces the most physiologically relevant GH pulse profile without adverse endocrine effects. The table below contrasts key pharmacological and selectivity parameters.
- CJC-1295 no DAC
- GHRH receptor (pituitary somatotrophs)
- ~30 minutes
- Minimal
- Pulsatile (mimics endogenous)
- Preclinical
- Ipamorelin
- GHSR-1a (ghrelin receptor)
- ~2 hours
- Minimal (5–8× lower than GHRP-6)
- Pulsatile (peaks 15–30 min)
- Phase II completed
- GHRP-6
- GHSR-1a + broad GPCR cross-reactivity
- ~2.5 hours
- Moderate to high
- Pulsatile but prolonged
- CJC-1295 with DAC
- GHRH receptor + albumin binding
- 6–8 days
- Minimal initially, increases with receptor desensitization
- Sustained supraphysiological
- Sermorelin
- GHRH receptor
- <10 minutes (without modification)
- Pulsatile but requires frequent dosing
- Phase III (approved for pediatric GHD)
- MK-677 (Ibutamoren)
- GHSR-1a (oral bioavailability)
- 4–6 hours
- Moderate (dose-dependent)
- Sustained (non-pulsatile)
- The combination of CJC-1295 no DAC and Ipamorelin produces the most favorable selectivity and pulsatility profile. GHRH receptor activation without albumin binding (preventing long-term receptor downregulation) paired with ghrelin receptor agonism that avoids cortisol and prolactin spikes. Research models using GHRP-6 or hexarelin frequently report appetite stimulation and cortisol elevation that confound metabolic endpoints. MK 677 offers oral convenience but produces sustained rather than pulsatile GH elevation, which animal studies associate with impaired insulin sensitivity after 8–12 weeks of continuous use.